Skip to main content

Drug-Fc Conjugates

Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment. These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system.




SARS-CoV-2 and
Other Viruses

Cidara’s Cloudbreak platform is a fundamentally new approach to treating and preventing serious diseases such as viral infections and solid tumors. By applying the principles of immuno-oncology, Cidara is creating a new generation of drugs that stably couple a highly potent drug targeting domain, a small molecule or a peptide, to an effector domain, a proprietary variant of a human antibody fragment (Fc). These long-acting, bispecific DFCs are designed to directly inhibit disease targets while simultaneously directing immune-mediated clearance of disease. The two distinct and complementary mechanisms are designed provide potency and selectivity, while also providing extended half-life and attract an immune response against the target virus or cancer cell to maximize disease eradicating activity.

Viral surface protein target
Infected cell surface
Natural killer cell surface

Cidara’s development candidate DFC CD388 is being studied in a Phase 1 clinical trial in partnership with Janssen for universal prevention and treatment of influenza.

Cidara is also advancing preclinical and discovery programs to target solid tumors as well as SARS-CoV-2.

DFCs are advancing through clinical, preclinical and discovery programs designed to target:


Solid Tumors

SARS-CoV-2 & Other Viruses